ADVERSE O
REACTIONS O
The O
majority O
of O
side O
effects O
observed O
in O
clinical O
trials O
were O
of O
a O
mild O
and O
transient O
nature O
. O

Fewer O
than O
3 O
% O
of O
adult O
patients O
without O
mycobacterial B-Not_AE_Candidate
infections I-Not_AE_Candidate
and O
fewer O
than O
2 O
% O
of O
pediatric O
patients O
without O
mycobacterial B-Not_AE_Candidate
infections I-Not_AE_Candidate
discontinued O
therapy O
because O
of O
drug-related O
side O
effects O
. O

Fewer O
than O
2 O
% O
of O
adult O
patients O
taking O
BIAXIN O
XL O
tablets O
discontinued O
therapy O
because O
of O
drug-related O
side O
effects O
. O

The O
most O
frequently O
reported O
events O
in O
adults O
taking O
BIAXIN O
tablets O
( O
clarithromycin O
tablets O
, O
USP O
) O
were O
diarrhea B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
taste I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
dyspepsia B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
/discomfort O
( O
2 O
% O
) O
, O
and O
headache B-OSE_Labeled_AE
( O
2 O
% O
) O
. O

In O
pediatric O
patients O
, O
the O
most O
frequently O
reported O
events O
were O
diarrhea B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
rash B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
and O
headache B-OSE_Labeled_AE
( O
2 O
% O
) O
. O

Most O
of O
these O
events O
were O
described O
as O
mild O
or O
moderate O
in O
severity O
. O

Of O
the O
reported O
adverse O
events O
, O
only O
1 O
% O
was O
described O
as O
severe O
. O

The O
most O
frequently O
reported O
events O
in O
adults O
taking O
BIAXIN O
XL O
( O
Clarithromycin O
extended-release O
tablets O
) O
were O
diarrhea B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
taste I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
and O
nausea B-OSE_Labeled_AE
( O
3 O
% O
) O
. O

Most O
of O
these O
events O
were O
described O
as O
mild O
or O
moderate O
in O
severity O
. O

Of O
the O
reported O
adverse O
events O
, O
less O
than O
1 O
% O
were O
described O
as O
severe O
. O

In O
the O
acute B-Not_AE_Candidate
exacerbation I-Not_AE_Candidate
of I-Not_AE_Candidate
chronic I-Not_AE_Candidate
bronchitis I-Not_AE_Candidate
and O
acute B-Not_AE_Candidate
maxillary I-Not_AE_Candidate
sinusitis I-Not_AE_Candidate
studies O
overall O
gastrointestinal B-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
were O
reported O
by O
a O
similar O
proportion O
of O
patients O
taking O
either O
BIAXIN O
tablets O
or O
BIAXIN O
XL O
tablets O
; O
however O
, O
patients O
taking O
BIAXIN O
XL O
tablets O
reported O
significantly O
less O
severe O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
compared O
to O
patients O
taking O
BIAXIN O
tablets O
. O

In O
addition O
, O
patients O
taking O
BIAXIN O
XL O
tablets O
had O
significantly O
fewer O
premature O
discontinuations O
for O
drug-related O
gastrointestinal B-NonOSE_AE
or O
abnormal O
taste O
adverse I-No
nOSE B-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
even I-OSE_Labeled_AE
ts I-NonOSE_AE
compared O
to O
BIAXIN O
tablets O
. O

In O
community B-Not_AE_Candidate
- I-Not_AE_Candidate
acquired I-Not_AE_Candidate
pneumonia I-Not_AE_Candidate
studies O
conducted O
in O
adults O
comparing O
clarithromycin O
to O
erythromycin O
base O
or O
erythromycin O
stearate O
, O
there O
were O
fewer O
adverse O
events O
involving O
the O
digestive O
system O
in O
clarithromycin-treated O
patients O
compared O
to O
erythromycin-treated O
patients O
( O
13 O
% O
vs O
32 O
% O
; O
p O
< O
0.01 O
) O
. O

Twenty O
percent O
of O
erythromycin-treated O
patients O
discontinued O
therapy O
due O
to O
adverse O
events O
compared O
to O
4 O
% O
of O
clarithromycin-treated O
patients O
. O

In O
two O
U.S O
. O
studies O
of O
acute B-Not_AE_Candidate
otitis I-Not_AE_Candidate
media I-Not_AE_Candidate
comparing O
clarithromycin O
to O
amoxicillin/potassium O
clavulanate O
in O
pediatric O
patients O
, O
there O
were O
fewer O
adverse O
events O
involving O
the O
digestive O
system O
in O
clarithromycin-treated O
patients O
compared O
to O
amoxicillin/potassium O
clavulanate-treated O
patients O
( O
21 O
% O
vs O
. O
40 O
% O
, O
p O
< O
0.001 O
) O
. O

One-third O
as O
many O
clarithromycin-treated O
patients O
reported O
diarrhea B-OSE_Labeled_AE
as O
did O
amoxicillin/potassium O
clavulanate-treated O
patients O
. O

Post-Marketing O
Experience O
Allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
ranging O
from O
urticaria B-OSE_Labeled_AE
and O
mild O
skin B-OSE_Labeled_AE
eruptions I-OSE_Labeled_AE
to O
rare O
cases O
of O
anaphylaxis B-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
with I-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DRESS I-OSE_Labeled_AE
) O
, O
Henoch B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Schonlein I-OSE_Labeled_AE
Purpura I-OSE_Labeled_AE
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
have O
occurred O
. O

Other O
spontaneously O
reported O
adverse O
events O
include O
glossitis B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
oral B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
and O
hemorrhage B-OSE_Labeled_AE
. O

There O
have O
been O
reports O
of O
tooth B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
in O
patients O
treated O
with O
BIAXIN O
. O

Tooth B-NonOSE_AE
discoloration I-NonOSE_AE
is O
usually O
reversible O
with O
professional O
dental O
cleaning O
. O

There O
have O
been O
isolated O
reports O
of O
hearing B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
which O
is O
usually O
reversible O
, O
occurring O
chiefly O
in O
elderly O
women O
. O

Reports O
of O
alterations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
sense I-OSE_Labeled_AE
of I-OSE_Labeled_AE
smell I-OSE_Labeled_AE
including O
smell B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
usually O
in O
conjunction O
with O
taste B-OSE_Labeled_AE
perversion I-OSE_Labeled_AE
or O
taste B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
have O
also O
been O
reported O
. O

Transient B-NonOSE_AE
CNS I-NonOSE_AE
events I-NonOSE_AE
including O
anxiety B-OSE_Labeled_AE
, O
behavioral B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
confusional B-OSE_Labeled_AE
states I-OSE_Labeled_AE
, O
convulsions B-OSE_Labeled_AE
, O
depersonalization B-OSE_Labeled_AE
, O
disorientation B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
manic B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
, O
nightmares B-OSE_Labeled_AE
, O
psychosis B-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
and O
vertigo B-OSE_Labeled_AE
have O
been O
reported O
during O
post-marketing O
surveillance O
. O

Events O
usually O
resolve O
with O
discontinuation O
of O
the O
drug O
. O

Adverse O
reactions O
related O
to O
hepatic B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
have O
been O
reported O
in O
postmarketing O
experience O
with O
clarithromycin O
. O

( O
See O
WARNINGS O
- O
Hepatotoxicity B-OSE_Labeled_AE
) O
. O

There O
have O
been O
rare O
reports O
of O
hypoglycemia B-OSE_Labeled_AE
, O
some O
of O
which O
have O
occurred O
in O
patients O
taking O
oral O
hypoglycemic O
agents O
or O
insulin O
. O

There O
have O
been O
post-marketing O
reports O
of O
BIAXIN O
XL O
tablets B-OSE_Labeled_AE
in I-OSE_Labeled_AE
the I-OSE_Labeled_AE
stool I-OSE_Labeled_AE
, O
many O
of O
which O
have O
occurred O
in O
patients O
with O
anatomic O
( O
including O
ileostomy B-Not_AE_Candidate
or O
colostomy B-Not_AE_Candidate
) O
or O
functional O
gastrointestinal B-Not_AE_Candidate
disorders I-Not_AE_Candidate
with I-Not_AE_Candidate
shortened I-Not_AE_Candidate
GI I-Not_AE_Candidate
transit I-Not_AE_Candidate
times I-Not_AE_Candidate
. O

As O
with O
other O
macrolides O
, O
clarithromycin O
has O
been O
associated O
with O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
and O
ventricular B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
, O
including O
ventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
and O
torsades B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
. O

There O
have O
been O
reports O
of O
interstitial B-OSE_Labeled_AE
nephritis I-OSE_Labeled_AE
coincident O
with O
clarithromycin O
use O
. O

There O
have O
been O
post-marketing O
reports O
of O
colchicine B-NonOSE_AE
toxicity I-NonOSE_AE
with O
concomitant O
use O
of O
clarithromycin O
and O
colchicine O
, O
especially O
in O
the O
elderly O
, O
some O
of O
which O
occurred O
in O
patients O
with O
renal B-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
. O

Deaths B-NonOSE_AE
have O
been O
reported O
in O
some O
such O
patients O
. O

( O
See O
WARNINGS O
and O
PRECAUTIONS O
. O
) O

There O
have O
been O
reports O
of O
rhabdomyolysis B-OSE_Labeled_AE
coincident O
with O
clarithromycin O
use O
. O

In O
some O
reports O
, O
clarithromycin O
was O
administered O
concomitantly O
with O
statins O
, O
fibrates O
, O
colchicine O
or O
allopurinol O
. O

Changes O
in O
Laboratory O
Values O
Changes O
in O
laboratory O
values O
with O
possible O
clinical O
significance O
were O
as O
follows O
: O
Hepatic O
Elevated B-OSE_Labeled_AE
SGPT I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) O
< O
1 O
% O
; O
SGOT O
( O
AST O
) O
< O
1 O
% O
; O
GGT O
< O
1 O
% O
; O
alkaline O
phosphatase O
< O
1 O
% O
; O
LDH O
< O
1 O
% O
; O
total O
bilirubin O
< O
1 O
% O
Hematologic O
Decreased B-OSE_Labeled_AE
WBC I-OSE_Labeled_AE
< O
1 O
% O
; O
elevated B-OSE_Labeled_AE
prothrombin I-OSE_Labeled_AE
time I-OSE_Labeled_AE
1 O
% O
Renal O
Elevated B-OSE_Labeled_AE
BUN I-OSE_Labeled_AE
4 O
% O
; O
elevated B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
< O
1 O
% O
GGT O
, O
alkaline O
phosphatase O
, O
and O
prothrombin O
time O
data O
are O
from O
adult O
studies O
only O
. O

